

ProteoPlex

advanced protein science

understand
macromolecular
proteins

MAX-PLANCK-GESellschaft

ProteoPlex GmbH

Im Vogelsang 10 | D-53179 Bonn | Germany

Managing Director: Joerg Wamser

+49 179 425 2884

joerg.wamser@proteoplex.de

www.proteoplex.de

Amtsgericht Bonn, HRB 22662

- 20S Proteasome, human -

| | |
|------------------------------------|---|
| Purity | >95% by SDS-PAGE |
| Specific activity | 60 nmol mg ⁻¹ min ⁻¹ (0.035 mg/mL (50nM) 20S Proteasome, substrate: Suc-LLVY-AMC (Bachem)) |
| Quantity | 7.5 mg/mL in 50 mM BisTris pH 6.5, 50 mM KCl, 10 MgCl ₂ , 10 mM DTT, 10 mM β-Glycerophosphate, 0.01% (w/v) LMNG |
| Source | HeLa cytoplasm |
| Molecular mass | 750 kDa |
| Crystallization condition | 7.5 mg/ml 20S Proteasome (mix 0.5 μl protein with 0.5 μl crystallization buffer (0.1M BisTris pH 6.5, 0.2M MgCl ₂ , 10% PEG3350). Crystals typically diffract to resolutions below 2.2 Angstroms. |
| Maximum resolution achieved | 1.8 Angstroms |
| Storage | At +4°C for 2 months |
| Reference | Schrader, J.; Henneberg, F.; Mata, R.; Tittmann, K.; Schneider, T.; Stark, H.; Bourenkov, G.; Chari, A.: The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design. Science Research Report, Vol. 353, Issue 6299, pp. 594-598 (2016) |